Vitreoretinal interface diseases are common causes of vision loss or metamorphopsia in spite of recent advances in clinical ophthalmology including vitreoretinal surgery, pharmacological therapy such as anti-VEGF agents, and gene-mediated therapy. The vitreous is often used as a therapeutic place or platform for these therapies; therefore, more detailed knowledge about the environment of the vitreous is required.
|Title of host publication||Vitreous|
|Subtitle of host publication||In Health and Disease|
|Publisher||Springer New York|
|Number of pages||14|
|Publication status||Published - Jan 1 2014|
All Science Journal Classification (ASJC) codes